Jun Cai

机构：Capital Medical University, Dalian University of Technology, Beijing Anzhen Hospital, Roche (China) · ORCID：0009-0000-0490-8727

发表论文 11 篇 · 总被引 84 次 · h-index 4

代表论文

• SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC). (2024 · Journal of Clinical Oncology · 被引 31)
• Dosimetric predictors of radiation pneumonitis in patients with prior immunotherapy exposure: A multi-institutional analysis (2023 · Radiotherapy and Oncology · 被引 21)
• Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial (2025 · The Lancet Oncology · 被引 11)
• Impacts of urban viaducts and noise barriers on traffic pollutant dispersion and residential exposure in the neighborhood: An analysis using large-eddy simulations (2025 · Building and Environment · 被引 9)
• Insight into the status of plasma renin and aldosterone measurement: findings from 526 clinical laboratories in China (2024 · Clinical Chemistry and Laboratory Medicine (CCLM) · 被引 4)
• Concordance among the three commercially available PD-L1 assays for esophageal squamous cell carcinoma. (2023 · Journal of Clinical Oncology · 被引 2)